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Background. During a World Health Organization–convened Guideline Development Group meeting, recom-
mendations for postexposure prophylaxis (PEP) for human immunodeﬁciency virus were made and research gaps
identiﬁed.
Methods. We used the PEP clinical management pathway and the Grading of Evidence, Assessment, Develop-
ment and Evaluation (GRADE) system as a framework to formulate future research questions, describe the most
feasible study design, and identify potential biases.
Results. Three key study design formats were identiﬁed to address 12 research questions: (1) survey- and inter-
view-driven research to identify barriers to access to PEP and related clinical care; (2) establishment of a global PEP
registry to generate data to inform the choice of an optimal PEP drug regimen, record drug toxicities arising from
speciﬁc PEP regimens, and track follow-up and linkage to care (including transition from PEP to preexposure pro-
phylaxis); and (3) randomized controlled trials to determine the optimal adherence promotion strategies necessary
for successful outcomes following PEP.
Conclusions. Positioning key clinical and programmatic research questions within the GRADE framework
facilitates the formulation of an evidence-based research agenda and future revisions of guidelines.
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In June 2014, the World Health Organization (WHO)
revised the global evidence-based recommendations
for the use of antiretrovirals for postexposure prophy-
laxis (PEP) to prevent human immunodeﬁciency virus
(HIV) transmission in the light of current evidence [1].
The process was supported by a Guideline Develop-
ment Group (GDG) of experts in the ﬁeld who reviewed
evidence from key systematic reviews to formulate new
recommendations for drug choice, prescribing
methods, and clinical management. An essential com-
ponent of any systematic review, as well as guideline de-
velopment, is the identiﬁcation of key research gaps. In
this article, we present potential approaches for the con-
duct of future HIV PEP research to overcome feasibility
or practical challenges that may arise. We demonstrate
how the Grading of Evidence, Assessment, Develop-
ment and Evaluation (GRADE) system can be used ef-
fectively as a conceptual framework and tool beyond the
determination and qualiﬁcation of recommendations to
identify future research priorities and methodological
challenges for research.
GRADE System
WHO has adopted the GRADE system for the develop-
ment of global clinical, programmatic, and public health
guideline recommendations [2]. The GRADE system
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allows for the explicit use of factors that can increase or decrease
the quality of the evidence from a starting point determined by
study design [3]. In addition to appraising the quality of evi-
dence, the GRADE approach includes an assessment of potential
beneﬁts and harms, resource utilization, and user values and
preferences. The GDG considers these elements together to
determine the direction and strength of a recommendation.
METHODS
Each recommendation made by the WHO HIV PEP GDG (see
Acknowledgements) was driven by an a priori clinical or pro-
grammatic question that was identiﬁed along the clinical man-
agement pathway for HIV PEP (Figure 1). A systematic review
conducted for each question and GRADE Evidence Proﬁle
tables summarizing the overall quality of evidence from each
systematic review were presented to the GDG. The GDG subse-
quently formulated a recommendation and determined the
strength of each recommendation.
For each stage on the clinical management pathway, we tabu-
lated the following: (1) the clinical or programmatic question; (2)
the recommendation formulated by the GDG or a record that no
recommendation was made; (3) the strength of each recommen-
dation where applicable; (4) the quality of evidence underpinning
the recommendation; (5) the most appropriate study design to
answer the research question; (6) conceptualization of a pragmat-
ic alternative study design if the ideal design was not feasible; and
(7) consideration of the methodological challenges of the study
design with the potential bias(es) identiﬁed.
In addition to making recommendations, the GDG experts
also considered the clinical management pathway of HIV PEP
and additional associated research gaps.
RESULTS
Table 1 provides an overview of future PEP research priorities
and the study design(s) considered most feasible to answer
each clinical or programmatic question. Overall, 3 key study de-
sign formats were identiﬁed to address 12 questions: (1) survey-
and interview-driven research to identify barriers to access to
PEP and related clinical care; (2) establishment of a global PEP
registry to generate data to inform the choice of an optimal
PEP drug regimen, to record drug toxicities arising from speciﬁc
PEP regimens, and to track follow-up and linkage to care (includ-
ing transition from PEP to preexposure prophylaxis [PrEP]); and
(3) randomized controlled trials (RCTs) to determine the opti-
mal adherence promotion strategies necessary for successful out-
comes following PEP.
DISCUSSION
We applied the GRADE framework to enhance the identiﬁcation
and description of the most appropriate and feasible research re-
quired to strengthen the evidence base for current and future PEP
recommendations. By taking into account both quality of the
available evidence and the strength of current recommendations,
we were able to clearly identify research gaps. Where recommen-
dations had not been made, expert knowledge of the PEP clinical
management pathway allowed the GDG to formulate key re-
search questions and identify the necessary study design. The
generation of new data to inform PEP guidelines is challenged
by the speciﬁc circumstances of the clinical encounter. HIV
transmission is a low-probability event (because of biological
and behavioral cofactors) and a high-consequence outcome for
the affected individual [4]. Hence, PEP administration is often
done in emergency settings, with high levels of anxiety expressed
by those who present for PEP. Yet, because of the low average
per-contact HIV risk, people who do not take PEP, or who initi-
ate treatment but are nonadherent, and who only sustain a dis-
crete high-risk exposure are not likely to become HIV infected.
The relative inefﬁciency of HIV transmission for the majority
of exposures that require PEP limits the ability to conduct ran-
domized trials of different PEP regimens, durations of treatment,
counseling protocols, and postregimen follow-up protocols.
Future Research Priorities
Qualitative Research
Identiﬁcation of barriers to accessing care is a key challenge in
ensuring timely and appropriate prescription of PEP. Expert
members of the GDG shared anecdotal reports of settings
Figure 1. Clinical management pathway of postexposure prophylaxis (PEP) and key clinical and programmatic questions.
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Table 1. Future Research Priorities Categorized According to the Postexposure Prophylaxis Clinical Management Pathway and Identiﬁed Using the GRADE Framework
Clinical or
Programmatic
Question
Current WHO
Recommendation
Strength of
Recommendation
Quality of
Evidence Ideal Study Design(s)
Feasibility and Practical
Constraints Alternative Study Design
Methodological Issues
Arising
Access
What are
provider
attitudes and
knowledge
regarding PEP
and PEP
prescribing
practices?
No recommendation—not
included as a question
in initial guideline
formulation
Not applicable Expert
opinion
Ethnographic observational
study of point of care and
audit of corresponding
medical records, using
diverse settings where
PEP may be prescribed
(eg, primary care clinics,
emergency rooms, STD
specialty clinics)
1. Time constraints within
emergency settings
2. Access to medical
records may be ethically
challenging
Cross-sectional survey of
providers regarding
knowledge, attitudes,
and practice of PEP
Selection bias: Those most
likely to participate may
be those providers who
are already familiar with
PEP.
Generalizability: PEP is
provided in diverse
settings, and the global
HIV epidemic affects
different populations in
different countries.
What barriers
exist to
accessing
PEP?
No recommendation—not
included as a question
in initial guideline
formulation
Not applicable Expert
opinion
Cross-sectional survey of
PEP recipients in all
settings
1. Potential difficulty
obtaining informed
consent in emergency
settings
2. High anxiety of
participants at access
point to PEP may
reduce levels of
participation
Qualitative interviews with
PEP recipients on
completion of PEP
course in specific
settings. Future
research may include
methods to overcome
barriers once these are
identified.
Recall bias: Data collected
after the point of access
may limit the accuracy of
participants’ responses.
PEP users who
experience barriers and/
or poor treatment may
be more likely to be lost
to follow-up.
Timing and duration of the intervention
Timing of PEP Within 72 h (best practice) Not applicable Very low RCT Ethical Adequately powered
animal studies
Generalizability of animal
data to humans;
equipoise of providers
Duration of PEP 28 d (best practice) Not applicable Very low RCT Ethical Adequately powered
animal studies
Generalizability of animal
data to humans;
equipoise of providers
Drug choice
What is the
optimal
number of
drugs to
prescribe for
PEP?
A 2-ARV-drug regimen is
effective, but 3 drugs
are preferred.
Conditional Low RCTs of comparative
effectiveness and safety
between 2- and 3-drug
regimens
An RCT would require a
large sample size for
adequate power to detect
significant differences.
HIV transmission is
inefficient; PEP numbers
at individual sites are low
and occur in a wide range
of settings, limiting the
desired sample size and
generalizability.
Cohort analysis following
recipients receiving
different regimens or
Global PEP Registry
Confounding: The impact
of additional exposure(s)
to HIV transmission
post–PEP regimen will
be a key confounder in a
cohort study. Provider
familiarity with PEP, and
site support for PEP,
may confound
interpretation of
regimens.
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Table 1 continued.
Clinical or
Programmatic
Question
Current WHO
Recommendation
Strength of
Recommendation
Quality of
Evidence Ideal Study Design(s)
Feasibility and Practical
Constraints Alternative Study Design
Methodological Issues
Arising
What are the
preferred
drugs to use
in the
backbone PEP
regimen in
adults and
adolescents?
TDF+3TC (or FTC) is
recommended as the
preferred backbone
regimen for HIV PEP in
adults and adolescents.
Strong Low to
moderate
RCTs of comparative
effectiveness and safety
between different ARV
drug regimens
Rapidly evolving profile of
recommended ARVs may
result in within-trial
regimen change.
As above, an RCT would
require high numbers for
adequate power to detect
significant difference.
Global PEP Registry Confounding: impact of
additional exposure to
HIV post PEP regimen.
Provider familiarity with
PEP, and site support for
PEP, may confound
interpretation of
regimens.
What is the
preferred third
drug(s) to use
for PEP in
adults and
adolescents?
LPV/r or ATV/r is
suggested as preferred
third drug for HIV PEP in
adults and adolescents.
Where available, the
following alternatives
can be considered:
DRV/r, RAL, EFV.
Conditional Very low As above As above As above As above
What are the
preferred
drugs to use
in the
backbone
regimen for
PEP for
children aged
≤10 y?
ZDV+3TC is
recommended as the
preferred backbone for
HIV PEP in children
aged ≤10 y. ABC+3TC
or TDF+3TC (or FTC)
can be considered as
alternative regimens.
Strong Low As above As above As above As above
What is the
preferred third
drug for PEP
for children
aged ≤10 y?
LPV/r is recommended as
the preferred third drug
for HIV PEP in children
aged ≤10 y.
ATV/r, RAL, NVP (if aged
<3), and EFV or DRV/r (if
3 y and older) can be
considered as
alternatives.
Conditional Very low As above As above As above As above
Adherence
Should 28 d (full)
vs starter
packs be used
for prescribing
PEP?
A full 28-d prescription of
ARVs should be
provided for HIV PEP
following initial risk
assessment.
Strong Very low No further research needed.
An RCT is unlikely to
change the strength of the
recommendation, which
was based on feasibility
and practical
implementation
considerations.
A Global PEP Registry will
allow identification of
those settings where
starter packs are still
provided. This will be for
monitoring and
evaluation purposes and
not research.
Confounding: Providers
and sites that use starter
packs may have other
characteristics that could
affect outcomes (eg,
more or less experience,
supportive
environment).
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Table 1 continued.
Clinical or
Programmatic
Question
Current WHO
Recommendation
Strength of
Recommendation
Quality of
Evidence Ideal Study Design(s)
Feasibility and Practical
Constraints Alternative Study Design
Methodological Issues
Arising
What types of
adherence
strategies
should be
offered during
PEP?
Enhanced adherence
counseling is suggested
for all individuals
initiating HIV PEP.
Conditionala Moderate An RCT comparing specific
adherence strategies in
the context of PEP
Sample size would be
extremely large, as
providing no adherence
support would likely be
considered unethical,
resulting in 2 active arms.
Documentation of
outcomes from single or
multisite PEP adherence
interventions with
comparison to historical
controls may provide
guidance for replication
in other settings; Global
PEP Registry would
require data fields to
describe diverse
interventions.
Confounding: May be
challenging to
randomize by patients
within sites, as the same
providers would be
required to deliver 2
different PEP adherence
interventions. Provider
and site characteristics
would make comparison
of interventions
randomized by site
difficult.
Follow-up and linkage to care
What is the
optimal
testing and
linkage to care
package for
PEP?
No—not included as a
question in initial
guideline formulation
Not applicable Expert
opinion
An RCT comparing different
strategies for post-PEP
testing
Sample size would be
extremely large, as
providing no follow-up
testing would be
considered unethical,
resulting in 2 active arms.
Documentation of
outcomes from single or
multisite post-PEP
testing algorithms with
comparison to historical
controls may provide
guidance for replication
in other settings; Global
PEP Registry would
require data fields to
describe diverse
interventions.
Confounding: Would
be challenging to
randomize by patients
within sites, as the same
providers would be
required to use 2
different PEP testing
algorithms.
Provider and site
characteristics would
make comparison of
testing algorithms
randomized by site
difficult.
When should
PEP be
transitioned to
PrEP?
No—not included as a
question in initial
guideline formulation
Not applicable Expert
opinion
An RCT comparing different
approaches to assess
patients for PEP, and to
triage them to PrEP
Sample size would be
extremely large; not
assessing any PEP
patients for PrEP could be
considered unethical,
resulting in 2 active arms.
Documentation of
outcomes from single or
multiple sites’ PEP-PrEP
triage programs, with
comparison to historical
controls, may provide
guidance for replication
in other settings; Global
PEP Registry would
require data fields to
describe diverse
algorithms and
programs for PEP-PrEP
transition.
Confounding: Would be
challenging to
randomize by patients
within sites, as the
decision to discuss PrEP
would be based on
numerous patient-
specific issues (eg,
likelihood of subsequent
repetitive HIV risk,
adherence to PEP
regimen, patient interest
in PrEP), making
comparison of triage
algorithms difficult.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ARV, antiretroviral; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; LPV/r,
ritonavir-boosted lopinavir; NVP, nevirapine; PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; RAL, raltegravir; RCT, randomized controlled trial; STD, sexually transmitted disease; TDF, tenofovir disoproxil
fumarate; WHO, World Health Organization; ZDV, zidovudine.
a This recommendation appears in the WHO 2013 Antiretroviral Therapy Consolidated Guidelines and was adopted for the PEP guidelines.
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where healthcare workers were reluctant to prescribe PEP and
concluded that there was a wide-scale lack of knowledge of
the beneﬁts of PEP among healthcare workers. Identiﬁcation
of the knowledge, attitudes, and prescription practices of PEP
providers with associated documentation of the care experienc-
es of PEP recipients would require survey- and interview-driven
research. Formulation of appropriate comparative questions
and evidence-based recommendations regarding the factors re-
quired to optimize delivery and receipt of PEP in the future
would only be possible once such baseline data were available.
Social desirability bias might limit the ability to be conﬁdent
that provider self-reports would mirror clinical practice.
Global Registry
Ideally, evidence to inform guidelines of interventions should be
based on data obtained from RCTs. Yet alternative study designs
must be considered when there are ethical, statistical, and practi-
cal challenges to the feasibility of conducting an RCT as outlined
in Table 1. Given that PEP is provided across many and varied
settings and PEP provision and uptake is generally low, the
GDG recommended that a global PEP registry be established to
standardize data reporting, to record toxicities due to PEP, to help
inform future PEP drug regimen choice for both adults and chil-
dren, and to potentially also provide information to track follow-
up and linkage to care. Registries have already been established
for other HIV research questions for which RCTs are not possible
[5], notably drug safety in pregnancy, and data generated from
such registries have directly informed WHO guidance [6].
RCTs of Adherence Strategies
Alternative methods of adherence support were considered in
the WHO 2013 antiretroviral therapy guidelines [7], and several
of these may be suitable to PEP (such as peer support, alarms,
text messaging, phone calls, and calendars), but the effective-
ness of these interventions for HIV-uninfected individuals in
the context of PEP has not been evaluated. At the same time,
it is recognized that adherence research is notoriously difﬁcult
owing to the small event-rate differences, limiting the ability of
any single trial to show signiﬁcant differences [8]. Future efforts
to identify interventions to improve adherence to PEP should
therefore be informed by HIV treatment and other medication
adherence research and lessons learned from similar interven-
tions, including, for example, PrEP [9], oral contraception,
and the management of hypertension, and treatment of latent
tuberculosis infection.
The Special Case of PEP to PrEP
When PEP was ﬁrst recommended for the prevention of occu-
pational HIV exposures [10], the presumption was that expo-
sures were not intentional and would be infrequent. The
recognition of settings of sexual assault, condom failure, and
discovery that a partner was HIV infected after exposure led
to the development of recommendations for the use of compa-
rable regimens for nonoccupational PEP [11]. Subsequent stud-
ies found that some nonoccupational PEP users presented more
than once, and a subset became recurrent users [12]. With the
subsequent determination that the preexposure use of antiretro-
virals could signiﬁcantly decrease HIV incidence (PrEP) [13], it
is clear that a subset of people presenting for PEP could beneﬁt
from PrEP [14]. Because many PEP users may not be at recur-
rent risk, new research studies are needed to assist front-line
PEP providers to efﬁciently determine which PEP users could
beneﬁt by transitioning to PrEP. Many of the nuances of opti-
mal management are discussed in the article by Jain et al in this
supplement [15], but further research is warranted, given the
newness of PrEP and the lack of a sufﬁcient evidence base to
suggest best practices.
Strengths and Limitations of the GRADE Approach to Prioritize
Research
The structure and direction of the GRADE framework provided
a useful starting point for the GDG discussions of future re-
search priorities. Low-quality evidence is the ﬁrst and most
powerful indicator of the need for future and/or more robust
research to underpin recommendations. The strength of a rec-
ommendation can also be informative, with conditional recom-
mendations generally indicating the need for further research
compared with recommendations rated as strong. However,
several WHO guidelines have included strong recommenda-
tions based on low-quality evidence [16]. Three of the recom-
mendations in these PEP guidelines are strong in the absence of
high-quality evidence. These include the recommendation for a
full 28-day prescription of antiretrovirals for HIV PEP following
initial risk assessment (rated as very low quality); the recom-
mendation for zidovudine (ZDV) plus lamivudine (3TC) as
the preferred backbone for HIV PEP in children aged ≤10
years and that abacavir plus 3TC or tenofovir disoproxil fuma-
rate (TDF) plus 3TC (or emtricitabine [FTC]) can be considered
as alternative regimens (rated as low quality); and the recom-
mendation that TDF plus 3TC (or FTC) is the preferred back-
bone regimen for HIV PEP in adults and adolescents (rated as
low to moderate quality). This apparent contradiction between
strength and ratings reﬂects that factors such as values, prefer-
ences, and resource utilization can drive the strength of the rec-
ommendation in addition to the quality of evidence.
Several clinical and programmatic questions were identiﬁed
directly from the PEP clinical management pathway based on
expert opinion gathered together in the GDG. We believe that
positioning these questions within the GRADE framework will
facilitate future revisions of the PEP guidelines given that the
key questions in association with the required study design
are well articulated, and can be addressed as new data emerge.
S210 • CID 2015:60 (Suppl 3) • Siegfried et al
Notes
Acknowledgments. We acknowledge the valuable inputs of the World
Health Organization (WHO) Post-Exposure Prophylaxis Guideline Develop-
ment Group: Linda Barlow-Mosha (Makerere University, John Hopkins Uni-
versity Research Collaboration, Uganda), 8 Ferenc Bagyinszky (European
AIDS Treatment Group, Belgium), Alexandra Calmy (Geneva University
Hospital, Switzerland), Mohamed Chakroun (Teaching Hospital, Faculty of
Medicine, University of Monastir, Tunisia), Esther Casas (Médecins Sans
Frontières, the Netherlands), Kenneth Dominguez (Centers for Disease
Control and Prevention, USA [CDC]), Kimberley Green (FHI 360 Ghana),
Jonathan Kaplan (CDC), Cristiane Rapparini (Riscobiologico.org Network,
Brazil), Htin Aung Saw (Specialist Hospital Mingalardone, Myanmar),
Francois Venter (WITS Reproductive Health and HIV Institute, South Afri-
ca), Zhao Yan (National Centre for AIDS/STD Prevention and Control, China
Center for Disease Control and Prevention, China). The following additional
WHO staff were part of the steering committee: Rachel L. Beanland, Meg
Doherty, Claudia Garcia Moreno Esteva, Jane Ferguson, Cadi Irvine, Martina
Penazzato, Francoise Renaud-Thery, Nathan Shaffer, and Marco Vitoria.
Financial support. This work was in part supported by funds from the
Bill & Melinda Gates Foundation.
Supplement sponsorship. This article appears as part of the supplement
“HIV Postexposure Prophylaxis,” sponsored by the World Health
Organization.
Potential conﬂicts of interest. K. H. M. has received unrestricted re-
search grants from Merck, Gilead, and Bristol-Myers Squibb. All other au-
thors report no conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Ford N, Mayer KH; for the World Health Organization Postexpo-
sure Prophylaxis Guideline Development Group. World Health
Organization guidelines on postexposure prophylaxis for HIV:
recommendations for a public health approach. Clin Infect Dis 2015;
60(suppl 3):S161–4.
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus
on rating quality of evidence and strength of recommendations. BMJ
2008; 336:924–6.
3. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduc-
tion-GRADE evidence proﬁles and summary of ﬁndings tables. J Clin
Epidemiol 2011; 64:383–94.
4. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimat-
ing per-act HIV transmission risk: a systematic review. AIDS 2014;
28:1509–19.
5. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral
pregnancy registry international interim report for 1 January 1989
through 31 January 2014. Wilmington, NC: Registry Coordinating
Center, 2014. Available at: www.APRegistry.com. Accessed 10 March
2015.
6. World Health Organization. Consolidated guidelines on general HIV
care and the use of antiretroviral drugs for treating and preventing
HIV infection: recommendations for a public health approach, 2013.
Available at: http://apps.who.int/iris/bitstream/10665/85321/1/
9789241505727_eng.pdf. Accessed 10 March 2015.
7. World Health Organization. Consolidated guidelines on the use of an-
tiretroviral drugs for treating and preventing HIV infection: recommen-
dations for a public health approach, 2013. Available at: http://apps.
who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf18. Ac-
cessed 18 November 2014.
8. Mills EJ, Lester R, Ford N. Adherence to antiretroviral therapy: super-
vision or support? Lancet Infect Dis 2012; 12:97–8.
9. Marcus JL, Buisker T, Horvath T, et al. Helping our patients take HIV
pre-exposure prophylaxis (PrEP): a systematic review of adherence in-
terventions. HIV Med 2014; 15:385–95.
10. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public
Health Service guidelines for the management of occupational exposures
to human immunodeﬁciency virus and recommendations for post-
exposure prophylaxis. Infect Control Hosp Epidemiol 2013; 34:
875–92.
11. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure
prophylaxis after sexual, injection-drug use, or other nonoccupational
exposure to HIV in the United States: recommendations from the U.
S. Department of Health and Human Services. MMWR Recomm Rep
2005; 54(RR-2):1–20.
12. Zablotska IB, Prestage G, Holt M, et al. Australian gay men who have
taken nonoccupational postexposure prophylaxis for HIV are in need of
effective HIV prevention methods. J Acquir Immune Deﬁc Syndr 2011;
58:424–8.
13. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylax-
is for HIV prevention in men who have sex with men. N Engl J Med
2010; 363:2587–99.
14. US Public Health Service. Preexposure prophylaxis for the prevention of
HIV in the United States—2014: a clinical practice guideline, 2014.
Available at: http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.
pdf. Accessed 21 August 2014.
15. Jain S, Krakower DS, Mayer KH. The transition from postexposure pro-
phylaxis to preexposure prophylaxis: an emerging opportunity for biobe-
havioral HIV prevention. Clin Infect Dis 2015; 60(suppl 3):S200–4.
16. Alexander PE, Bero L, Montori VM, et al. World Health Organization
recommendations are often strong based on low conﬁdence in effect es-
timates. J Clin Epidemiol 2014; 67:629–34.
Future Research Agenda for PEP • CID 2015:60 (Suppl 3) • S211
